Alvotech

Equities

ALVO

LU2458332611

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
14.15 ^USD	+3.66%		+7.03%	+23.26%

Apr. 25	Cigna to offer Humira rivals with $0 copay at specialty pharmacy	RE
Apr. 24	Alvotech’s Simponi Biosimilar Candidate Shows Efficacy in Confirmatory Study	MT

Alvotech Reports Earnings Results for the Full Year Ended December 31, 2023

March 20, 2024 at 04:33 pm EDT

Alvotech reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 551.73 million compared to USD 513.58 million a year ago. Basic loss per share from continuing operations was USD 2.43 compared to USD 2.6 a year ago.

Latest news about Alvotech

Cigna to offer Humira rivals with $0 copay at specialty pharmacy	Apr. 25	RE
Alvotech’s Simponi Biosimilar Candidate Shows Efficacy in Confirmatory Study	Apr. 24	MT
Alvotech Announces Topline Results from A Confirmatory Clinical Study for AVT05, A Proposed Biosimilar for Simponi	Apr. 24	CI
Sector Update: Health Care Stocks Advance Late Afternoon	Apr. 19	MT
Sector Update: Health Care Stocks Rise Friday Afternoon	Apr. 19	MT
Sector Update: Health Care	Apr. 19	MT
Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	Apr. 19	MT
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	Apr. 19	MT
Alvotech Signs U.S. Agreement to Expand Access for Newly Approved High-Concentration Interchangeable Biosimilar to Humira®	Apr. 19	CI
Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)	Apr. 17	CI
Alvotech, Teva Win US FDA Approval for Selarsdi Injection to Treat Severe Plaque Psoriasis, Psoriatic Arthritis	Apr. 16	MT
Alvotech, Teva Get FDA Approval for Stelara Biosimilar Psoriasis Treatment	Apr. 16	DJ
J&J beats first-quarter profit estimates on cancer drugs strength	Apr. 16	RE
Transcript : Alvotech - Special Call	Apr. 03
Barclays Raises Price Target on Alvotech to $20 From $17, Maintains Overweight Rating	Mar. 22	MT
Transcript : Alvotech - Analyst/Investor Day	Mar. 22
Alvotech Provides Earnings Guidance for the Year 2024 and 2025	Mar. 21	CI
Transcript : Alvotech, 2023 Earnings Call, Mar 21, 2024	Mar. 21
Alvotech Full-Year 2023 Loss Narrows, Revenue Rises	Mar. 20	MT
Alvotech Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Alvotech Announces Executive Changes	Feb. 29	CI
Global markets live: Domino's Pizza, Walt Disney, Broadcom, Ryanair, Exxon Mobil, Goldman Sachs...	Feb. 26
Sector Update: Health Care Stocks Mixed Premarket Monday	Feb. 26	MT
How long will this bullish phase last?	Feb. 26
Alvotech, Teva Say Simlandi Receives US FDA Approval as Interchangeable Humira Biosimilar	Feb. 26	MT

Chart Alvotech

Duration

Period

More charts

Company Profile

Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Companyâs pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.

Sector

Biotechnology & Medical Research

Calendar

2024-05-20 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Alvotech

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

14.15 USD

Average target price

16.5 USD

Spread / Average Target

+16.61%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ALVOTECH	+23.26%	3.96B
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+48.32%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research